CA3003563A1 - Virulence attenuated bacteria for treatment of malignant solid tumors - Google Patents

Virulence attenuated bacteria for treatment of malignant solid tumors Download PDF

Info

Publication number
CA3003563A1
CA3003563A1 CA3003563A CA3003563A CA3003563A1 CA 3003563 A1 CA3003563 A1 CA 3003563A1 CA 3003563 A CA3003563 A CA 3003563A CA 3003563 A CA3003563 A CA 3003563A CA 3003563 A1 CA3003563 A1 CA 3003563A1
Authority
CA
Canada
Prior art keywords
bacterial strain
negative bacterial
proteins
protein
attenuated gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3003563A
Other languages
English (en)
French (fr)
Inventor
Simon ITTIG
Marlise AMSTUTZ
Christoph Kasper
Guy R. Cornelis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of CA3003563A1 publication Critical patent/CA3003563A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3003563A 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors Pending CA3003563A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15195490.6 2015-11-19
EP15195490 2015-11-19
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Publications (1)

Publication Number Publication Date
CA3003563A1 true CA3003563A1 (en) 2017-05-26

Family

ID=54697464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003563A Pending CA3003563A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Country Status (24)

Country Link
US (1) US11166987B2 (https=)
EP (2) EP3377094B1 (https=)
JP (1) JP7060503B2 (https=)
KR (1) KR102736981B1 (https=)
CN (1) CN108472348B (https=)
AU (1) AU2016358257B2 (https=)
BR (2) BR112018009753B1 (https=)
CA (1) CA3003563A1 (https=)
CY (1) CY1124564T1 (https=)
DK (1) DK3377094T3 (https=)
EA (1) EA201890868A1 (https=)
ES (1) ES2880431T3 (https=)
HR (1) HRP20211191T1 (https=)
HU (1) HUE055132T2 (https=)
IL (1) IL259052B2 (https=)
LT (1) LT3377094T (https=)
PL (1) PL3377094T3 (https=)
PT (1) PT3377094T (https=)
RS (1) RS62152B1 (https=)
SG (1) SG11201803643TA (https=)
SI (1) SI3377094T1 (https=)
SM (1) SMT202100423T1 (https=)
WO (1) WO2017085233A1 (https=)
ZA (1) ZA201803902B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102648293B1 (ko) 2014-05-21 2024-03-15 우니페르시테트 바젤 세균 기반 단백질 전달
IL259050B2 (en) 2015-11-19 2024-03-01 Univ Basel Bacteria-based protein delivery
EP3957645A1 (en) 2016-12-20 2022-02-23 Universität Basel Virulence attenuated bacteria based protein delivery
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
MX2023004760A (es) * 2020-10-27 2023-07-21 T3 Pharmaceuticals Ag Suministro de proteinas basado en bacterias.
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用
CN116064877B (zh) * 2023-02-09 2024-09-20 宁夏大学 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法
CN116855496B (zh) * 2023-07-05 2024-08-16 郑州大学 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用
WO2025037284A2 (en) * 2023-08-17 2025-02-20 Baccine Ltd. Genetically modified bacteria for multi-modal secretion of a neoantigen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (en) 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
AU2001294834A1 (en) 2000-09-26 2002-04-08 Beth Israel Deaconess Medical Center Recombinant bcg vaccines for the prevention and treatment of cancer
WO2002077249A2 (en) * 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
EP1943344A2 (en) 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2268313A2 (en) 2008-03-17 2011-01-05 Universitätsklinikum Münster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
AU2012267176B2 (en) 2011-06-08 2017-06-15 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
KR102648293B1 (ko) 2014-05-21 2024-03-15 우니페르시테트 바젤 세균 기반 단백질 전달
IL259050B2 (en) 2015-11-19 2024-03-01 Univ Basel Bacteria-based protein delivery
EP3957645A1 (en) 2016-12-20 2022-02-23 Universität Basel Virulence attenuated bacteria based protein delivery

Also Published As

Publication number Publication date
CN108472348A (zh) 2018-08-31
KR102736981B1 (ko) 2024-12-02
IL259052B2 (en) 2024-03-01
AU2016358257A1 (en) 2018-05-10
PL3377094T3 (pl) 2021-12-13
ES2880431T3 (es) 2021-11-24
US20190015497A1 (en) 2019-01-17
EP3377094B1 (en) 2021-04-28
BR112018009753B1 (pt) 2024-02-20
BR122023024697A2 (pt) 2023-12-26
CY1124564T1 (el) 2022-07-22
SMT202100423T1 (it) 2021-09-14
US11166987B2 (en) 2021-11-09
HRP20211191T1 (hr) 2021-10-29
AU2016358257B2 (en) 2023-08-17
WO2017085233A1 (en) 2017-05-26
IL259052A (en) 2018-07-31
LT3377094T (lt) 2021-08-10
HUE055132T2 (hu) 2021-11-29
HK1256137A1 (en) 2019-09-13
BR112018009753A2 (pt) 2018-11-13
EP3903813A1 (en) 2021-11-03
PT3377094T (pt) 2021-07-08
KR20180081583A (ko) 2018-07-16
JP7060503B2 (ja) 2022-04-26
CN108472348B (zh) 2022-12-27
EP3377094A1 (en) 2018-09-26
IL259052B1 (en) 2023-11-01
SI3377094T1 (sl) 2021-09-30
EA201890868A1 (ru) 2018-12-28
ZA201803902B (en) 2019-03-27
SG11201803643TA (en) 2018-06-28
BR112018009753A8 (pt) 2019-02-26
DK3377094T3 (da) 2021-08-02
JP2019500026A (ja) 2019-01-10
RS62152B1 (sr) 2021-08-31

Similar Documents

Publication Publication Date Title
US11166987B2 (en) Virulence attenuated bacteria for treatment of malignant solid tumors
US20240401065A1 (en) Bacteria-Based Protein Delivery
US11702663B2 (en) Bacteria-based protein delivery
HK1256137B (en) Virulence attenuated bacteria for treatment of malignant solid tumors
EA040558B1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
CA3005380C (en) Bacteria-based protein delivery
HK1256138B (en) Bacteria-based protein delivery
HK1236208A1 (en) Bacteria-based protein delivery
HK40015324A (en) Virulence attenuated bacteria based protein delivery
HK40015324B (en) Virulence attenuated bacteria based protein delivery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241107

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241107

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250717

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250717

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251104